Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group streptococci.
We investigated the role of viridans group streptococci in the prevention of colonization with methicillin-resistant Staphylococcus aureus (MRSA) in neonatal intensive care units. During a 26-month period at a children's hospital, 207 (49.9%) of 415 newborns were colonized with MRSA by the time of discharge. Two groups of newborns with matching durations of hospitalization were compared with regard to the prevalence of future colonization with MRSA: group 1 (103 patients) did not acquire colonization with viridans group streptococci and group 2 (63 patients) did acquire colonization with viridans group streptococci at birth or by 1 to 2 weeks (age, < or =11 days). The rate of colonization among patients in group 2 (9.5%) was significantly lower than that among patients in group 1 (44.7%; P<.001). No significant difference in patient characteristics (e.g., birth weight, diseases) was observed. These results indicate that viridans group streptococci, as bacteria that formerly occupied the oral cavities in newborns, may inhibit later colonization with MRSA.
Uehara
Y
Y
Division of Clinical Pathology, Nagano Children's Hospital, Toyoshina, Japan. ue3527@jeans.ocn.ne.jp
Kikuchi
K
K
Nakamura
T
T
Nakama
H
H
Agematsu
K
K
Kawakami
Y
Y
Maruchi
N
N
Totsuka
K
K
D000898:Antibiosis; D006801:Humans; D007231:Infant, Newborn; D007363:Intensive Care Units, Neonatal; D016106:Methicillin Resistance; D009055:Mouth / Q000382:microbiology*; D009666:Nose / Q000382:microbiology*; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development*; D013291:Streptococcus / Q000254:growth & development*